Pfizer Inc announced today that the Phase 3 INTORSECT ( B1771003 ) study, evaluating TORISEL ( temsirolimus ) in patients with advanced renal cell carcinoma ( RCC ) whose disease had progressed on or after SUTENT ( sunitinib malate ) therapy, did not meet the primary endpoint of prolonging progression free survival ( PFS ) when compared to sorafenib .